Join to View Full Profile
450 Brookline AveDana Farber Cancer Center - Smith 353Boston, MA 02215
Phone+1 617-632-3779
Fax+1 617-632-5822
Dr. Nikiforow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013
Yale-New Haven Medical CenterResidency, Internal Medicine, 2005 - 2008
Yale School of MedicineClass of 2005
Certifications & Licensure
MA State Medical License 2010 - 2026
CT State Medical License 2008 - 2010
American Board of Internal Medicine Hematology
Clinical Trials
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH Start of enrollment: 2020 Jun 02
Publications & Presentations
PubMed
- Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.Corey Cutler, Haesook T Kim, Hassan El Banna, Elizabeth Halloran, Emily Matozel
Journal of Clinical Oncology. 2026-06-01 - Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.Adam S Sperling, Benjamin A Derman, Sarah Nikiforow, Alejandro Alonso, Shuntaro Ikegawa
Science Translational Medicine. 2026-05-27 - Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.Luis E Aguirre, Haesook T Kim, Hany Elmariah, Stacey M Frumm, Amar H Kelkar
Blood Advances. 2026-04-28
Journal Articles
- Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-cell TherapySarah Nikiforow, Caron Jacobson, JAMA Neurology
Abstracts/Posters
- A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...Sarah Nikiforow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...Sarah Nikiforow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host DiseaseSarah Nikiforow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck CancersFebruary 11th, 2021
Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 1st, 2017
The Fantastic Voyage of a Bag of Cells Shipped West to Be Trained in the Art of Killing CancerOctober 27th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
